14 stories mentioning ASX:MSBUpdated 8d ago
Every FINWIRES story that references ASX:MSB, newest first.
Mesoblast (ASX:MSB) said JPMorgan Chase & Co. and its affiliates ceased to be substantial holders of the firm on July 17, according to a Wednesday Australian bourse filing.Its shares rose 1% in recent trading on Wednesday.
(Updates with the stock movement in the headline and last paragraph.)Mesoblast (ASX:MSB) CEO Silviu Itescu increased his holdings in the company to about 80.8 million common shares through the exercise of about 1.9 million options at a price of AU$1.45 each, according to a Tuesday filing with the Australian bourse.Itescu, the company's founder, paid Mesoblast about AU$2.7 million to exercise the options, per the filing."The investment reflects my strong confidence in Mesoblast's continued growth trajectory and its value proposition," the executive said.The company's shares fell 5% in recent Tuesday trade.
Mesoblast (ASX:MSB) CEO Silviu Itescu increased his holdings in the company to about 80.8 million common shares through the exercise of about 1.9 million options at a price of AU$1.45 each, according to a Tuesday filing with the Australian bourse.Itescu, the company's founder, paid Mesoblast about AU$2.7 million to exercise the options, per the filing."The investment reflects my strong confidence in Mesoblast's continued growth trajectory and its value proposition," the executive said.
Here are the ASX-listed companies with the biggest losses on Friday.EQ Resources (ASX:EQR): -10%, AU$0.22Mesoblast (ASX:MSB): -10%, AU$2.50Orezone Gold (ASX:ORE): -8%, AU$2.07Ora Banda Mining (ASX:OBM): -8%, AU$0.99Regis Resources (ASX:RRL): -8%, AU$5.69Sunrise Energy Metals (ASX:SRL): -7%, AU$15.744DMedical (ASX:4DX): -7%, AU$3.49Weebit Nano (ASX:WBT): -7%, AU$6.04Elsight (ASX:ELS): -7%, AU$6.74Metals X (ASX:MLX): -7%, AU$1.35
Mesoblast (ASX:MSB) achieved its target to treat at least 300 patients in a phase 3 trial of rexlemestrocel-L for chronic lower back pain linked to degenerative disc disease, according to a Tuesday filing with the Australian bourse.The trial's primary endpoint targets a significant difference in the reduction of lower back pain between rexlemestrocel-L and sham controls after 12 months of treatment, while secondary endpoints include improvements in function, quality of life, and a halting of pain medications.Rexlemestrocel-L obtained regenerative medicine advanced therapy designation from the US Food and Drug Administration, and the trial's topline results are due in mid-2027, the company said.Mesoblast shares fell past 1% in recent Tuesday trade.
Mesoblast (ASX:MSB) reported net revenue of $36 million from sales of its Ryoncil mesenchymal stromal cell therapy product in the fiscal fourth quarter, compared with Jefferies' estimate of $32.4 million, according to a Friday note by the investment firm.Jefferies estimated 34 patients received treatment in the quarter, with around 20 patients having completed treatment. It now expects 85 patients, up from the previous 82, completed therapy in fiscal year 2026.The investment firm assigned Mesoblast a buy rating and retained its price target of AU$2.80 per share.
Mesoblast (ASX:MSB) said its Ryoncil product achieved its first full year of net revenue in the amount of $115 million in the fiscal year ended June 30, exceeding the company's initial projections, according to a Friday Australian bourse filing.Net revenue for Ryoncil, a treatment approved for steroid-refractory acute graft versus host disease in pediatric patients, was $36 million for the fiscal fourth quarter, the company said.The new five-year facility has freed up the company's label extension and products for strategic initiatives, Mesoblast Chief Executive Silviu Itescu said.Mesoblast's shares rose nearly 5% in recent trading on Friday.
Mesoblast (ASX:MSB) received a biologics license application (BLA) filing number from the US Food and Drug Administration (FDA) for rexlemestrocel-L in the prevention of gastrointestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device, according to a Wednesday filing with the Australian bourse.BLA filing number is a six-digit tracking number issued by the FDA to identify and monitor a formal request to market a biologic product.The company also requested a modular review of its BLA for the therapy, the filing said.Shares rose 3% in morning trade on Wednesday.
Mesoblast (ASX:MSB) said it drew down $50 million from a five-year facility provided by Gregory George, a shareholder and director of the company, according to a Thursday filing with the Australian bourse.The credit line carries a fixed interest rate of 8% per year, which marks "a substantial reduction" from prior facilities, the company said.Mesoblast had $122 million of cash at the end of March and "is well funded to invest in its commercial operations and growth pipeline," it said.The company's shares fell nearly 2% in recent Thursday trade.
Mesoblast (ASX:MSB) said JPMorgan Chase and its affiliates ceased to be substantial holders of the firm on Tuesday, according to a Friday Australian bourse filing.Its shares rose 1% in recent trading on Friday.
Mesoblast (ASX:MSB) said gross sales for Ryoncil, its mesenchymal stromal cell product, during the March quarter were $35.3 million, according to a Thursday Australian bourse filing.Net revenue was $30.3 million, bringing the revenue generated during the first year of the product's launch to nearly $100 million, per the filing.Receipts from customers were $34.6 million in the March quarter, compared with $1.5 million in the year-ago period.Mesoblast's shares fell nearly 5% in recent trading on Thursday.
Mesoblast (ASX:MSB) achieved the recruitment target of at least 300 patients for a phase 3 clinical trial of rexlemestrocel-L for the treatment of chronic lower back pain associated with degenerative disc disease, according to a Wednesday filing with the Australian bourse.The placebo-controlled study will randomize patients to a single intradiscal injection of the company's proprietary allogeneic stromal cell therapy or sham control for 12 months, with its primary endpoint being a significant difference in the reduction of lower back pain, per the filing.The trial's secondary endpoints include improvements in function, quality of life, and cessation of pain medication including opioids.The company expects to see top-line results in mid-2027.Shares of Mesoblast gained nearly 5% in recent Wednesday trade.
Australian shares were flat with a positive bias on Wednesday's close as investors weighed reports of a second round of peace talks between the US and Iran.The S&P/ASX 200 Index was little changed to close at 8,978.70.US President Donald Trump said talks with Iran could resume in Pakistan over the next two days, even as a US naval blockade on Iranian ports continued. Brent crude oil futures rose 1% to $95.77 per barrel.On Wall Street, the Nasdaq was up nearly 2% on Tuesday, and the S&P 500 climbed 1.2%.On the domestic front, the International Monetary Fund (IMF) cut its economic growth projections for Australia, with gross domestic product (GDP) growth rate now expected to come in at 2% in 2026, compared with the previous forecast of 2.1%, and 1.7% in 2027, down from the earlier forecast of 2.2%.Australia's private sector credit is projected to grow by 7.2% year over year this year, tracking at its fastest pace since 2022, before slowing to 5.7% year-over-year by late 2027, ANZ said in a report.Australian consumer spending rose 2.1% in March, month-on-month, driven by a sharp increase in fuel spending due to higher prices, according to NAB's consumer spend trend report.In company news, Virgin Australia Holdings (ASX:VGN) said that its fiscal year 2026 financial guidance remains unchanged, with the underlying earnings before interest and taxes (EBIT) and underlying EBIT margin in the second half expected to be higher than the prior-year period. Its shares were up 7% on market close.Mesoblast (ASX:MSB) acquired an exclusive license to a patented chimeric antigen receptor technology platform to boost the effectiveness of its products. Its shares rose 7% at close.Lastly, Yancoal Australia (ASX:YAL) said that it entered into binding transaction documentation with EMR Capital Advisors, Kestrel Coal (EMR), Adaro Capital, and EMR Capital Management to acquire Kestrel Coal Group, which holds an 80% interest in the Kestrel coal mine joint venture in Queensland, for up to $2.4 billion. Its shares closed down 2%.
Mesoblast (ASX:MSB) acquired an exclusive license to a patented chimeric antigen receptor technology platform to boost the effectiveness of its products, according to a Wednesday filing with the Australian bourse.The company obtained the rights to the intellectual property developed at Mayo Clinic through the acquisition of a startup mainly formed to advance the technology, the filing said.Shares rose nearly 7% in morning trade Wednesday.
